Compassionate Use of Mifepristone in Brain/Nervous System and Other Cancers

New Mexico Cancer Care Alliance

Status

Terminated

Conditions

Cancer

Treatments

Drug: Mifepristone

Study type

Interventional

Funder types

Other

Identifiers

NCT00832871

INST 0817

NCI-2011-02682 (Registry Identifier)

Details and patient eligibility

About

The purpose of this study is to see if mifepristone prevents worsening of your cancer. Mifepristone is an antiprogesterone agent, a drug which blocks female hormones, that is commonly used for the termination of pregnancies. It has not been approved by the Food and Drug Administration for use in the treatment of cancer. It is unlicensed in the United States for your condition. However, previous work has indicated that mifepristone may be useful due to how it works. It is being made available for use in the United States for compassionate use through the Feminist Majority Foundation.

Full description

This is a compassionate use of mifepristone treatment for patients with conditions that could respond to an antiprogesterone agent, including:

Meningioma.
Breast cancer
Colon Cancer
Endometrial Stromal Sarcoma
Bilateral Chronic Central Serous Retinopathy
Cushing's Syndrome
Metastatic Adrenocortical Cancer
Ovarian Cancer
Other conditions as determined by the attending physicians

Enrollment

4 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

All patients 18 years of age or older.
Patients must sign an informed consent.
Patients should be in such a health condition in the opinion of the attending physician that with the administration of mifepristone benefits may outweigh risks.

Exclusion criteria